SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 278 filers reported holding SAGE THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $452,000 | -2.4% | 14 | 0.0% | 0.00% | – |
Q1 2022 | $463,000 | -22.3% | 14 | 0.0% | 0.00% | – |
Q4 2021 | $596,000 | -3.9% | 14 | 0.0% | 0.00% | – |
Q3 2021 | $620,000 | -97.0% | 14 | -96.4% | 0.00% | -100.0% |
Q2 2021 | $20,459,000 | -29.9% | 390 | 0.0% | 0.01% | -37.5% |
Q1 2021 | $29,190,000 | -13.5% | 390 | 0.0% | 0.01% | -20.0% |
Q4 2020 | $33,737,000 | +9092.6% | 390 | +6400.0% | 0.01% | – |
Q3 2020 | $367,000 | +47.4% | 6 | 0.0% | 0.00% | – |
Q2 2020 | $249,000 | +44.8% | 6 | 0.0% | 0.00% | – |
Q1 2020 | $172,000 | -61.7% | 6 | 0.0% | 0.00% | – |
Q4 2019 | $449,000 | -46.7% | 6 | 0.0% | 0.00% | – |
Q3 2019 | $842,000 | -23.3% | 6 | 0.0% | 0.00% | – |
Q2 2019 | $1,098,000 | +15.1% | 6 | 0.0% | 0.00% | – |
Q1 2019 | $954,000 | +65.9% | 6 | 0.0% | 0.00% | – |
Q4 2018 | $575,000 | -31.1% | 6 | 0.0% | 0.00% | – |
Q3 2018 | $834,000 | -99.2% | 6 | -99.1% | 0.00% | -100.0% |
Q2 2018 | $103,215,000 | -0.1% | 662 | 0.0% | 0.02% | -19.0% |
Q1 2018 | $103,305,000 | – | 662 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |